System Dynamics of PD-1 Signaling in T Cells
T 细胞中 PD-1 信号传导的系统动力学
基本信息
- 批准号:10211871
- 负责人:
- 金额:$ 78.46万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-05-03 至 2027-04-30
- 项目状态:未结题
- 来源:
- 关键词:AccountingAffinityAntibodiesAntigen PresentationAntigen-Presenting CellsAntigensAutoimmune DiseasesAutoimmunityB7-DC antigenBioinformaticsBiological AssayCD28 geneCD8-Positive T-LymphocytesCD80 geneCD86 geneCell LineCellsChronicClustered Regularly Interspaced Short Palindromic RepeatsComplementDataDiseaseEngineeringEvaluationFamilyFluorescence MicroscopyFormulationHumanITAMImmuneImmune TargetingImmune responseImmune systemImmunologic SurveillanceImmunotherapyIndividualInnate Immune ResponseInterventionInvestigationKnowledgeLabelLigandsMachine LearningMass Spectrum AnalysisMeasurementMeasuresMediatingMembraneMethodsModelingMolecularMonitorNR0B2 geneOncologyPTPN11 genePTPN6 genePatternPhosphoric Monoester HydrolasesPhosphorylationPhosphotransferasesPhosphotyrosinePlayPopulationProtein DephosphorylationProtein Tyrosine KinaseProtein Tyrosine PhosphataseProteinsProtocols documentationReagentReceptor SignalingRoleSYK geneSamplingSignal TransductionSignaling ProteinSiteStructural ModelsSystemSystems BiologyT-Cell ActivationT-Cell ReceptorT-LymphocyteTechniquesTestingTherapeutic antibodiesTimeToll-like receptorsTyrosine PhosphorylationValidationWestern BlottingZAP-70 Geneadaptive immune responsearmbasecancer cellchronic infectiondectin 1exhaustionexperimental studyimmune activationimmune checkpointimprovedinterestmathematical modelneoplastic cellnovel therapeutic interventionparticlepathogenpathogenic fungusphosphoproteomicspredictive modelingpreventprogrammed cell death ligand 1programmed cell death protein 1receptorrecruitresponsesingle molecule
项目摘要
PROJECT SUMMARY/ABSTRACT
Adaptive immune responses are governed by T cell receptor (TCR) signaling, which determines the fates and
activities of T cells (helper, effector, etc.). The TCR and its signaling partners integrate antigen-recognition
signals and second signals, which carry information about the context in which antigen presentation is
occurring. Second signals can be either stimulatory or inhibitory: stimulatory signals are essential for T cell
activation, whereas inhibitory signals (also called checkpoints) are responsible for T cell exhaustion and
antigen tolerance. Stimulatory second signals are generated by the innate arm of the immune system when, for
example, signaling by Toll-like receptors induces expression of the B7-family ligands B7-1 (CD80) and B7-2
(CD86) on antigen-presenting cells. Expression of B7-1/B7-2 indicates that antigen presentation is occurring
within the context of an ongoing innate immune response. B7-1 and B7-2 are recognized by CD28, a TCR
coreceptor that potently enhances TCR-generated T-cell activation signals. Inhibitory second signals arise
during the course of chronic stimulation of TCR signaling. They are important for limiting the collateral damage
caused by an immune response and avoidance of autoimmunity, but they can also be deleterious. For
example, tumor cells commonly express the B7-family ligands B7-H1 (PD-L1/CD274) and B7-DC (PD-
L2/CD273), which are recognized by PD-1, a TCR coreceptor that inhibits TCR-generated T-cell activation
signals. B7-H1/B7-DC expression conveys immune privilege to tumor cells. For these and other reasons, it is
imperative that we improve our basic understanding of checkpoint signaling. Here, we propose to characterize
the dynamics of PD-1-regulated tyrosine phosphorylation in Jurkat E6-1, HuT 78, and TALL-104 cells,
CRISPR-engineered cells derived from these parental cell lines, and primary human CD8+ cells. We will apply
quantitative mass spectrometry (MS) to obtain an unbiased, nearly comprehensive picture of phosphotyrosine
(pTyr) site abundances with and without PD-1/CD28 coreceptor signaling in populations of T cells over time
and across conditions. Concurrently, using fluorescence microscopy and engineered SH2 domain affinity
reagents, we will characterize single-molecule patterns of multisite phosphorylation for TCR, CD28, and PD-1.
We will also measure membrane-recruitment lifetimes for individual cytosolic signaling partners of these
receptors. The resulting data will be used to drive the formulation and parameterization of a detailed
mechanistic model for TCR signaling accounting for the effects of CD28 and PD-1 coactivation. Although PD-1
is viewed as a platform for recruitment of phosphatases that counteract activation signals from kinases, we will
evaluate specific hypotheses about how PD-1 could potentially generate positive signals for T-cell activation.
These hypotheses are motivated by the fact that the best characterized signaling partners of PD-1 are protein
tyrosine phosphatases, SHP1 and SHP2, which are known to promote cell activation in other contexts by, for
example, mediating the dephosphorylation of inhibitory pTyr sites. Model predictions will be tested.
项目摘要/摘要
获得性免疫反应受T细胞受体(TCR)信号支配,TCR信号决定命运和
T细胞的活动(辅助者、效应者等)。TCR及其信号伙伴整合了抗原识别
信号和第二信号,它们携带关于抗原呈递的上下文的信息
发生的。第二种信号既可以是刺激性的,也可以是抑制性的:刺激性信号对T细胞是必不可少的
激活,而抑制信号(也称为检查点)负责T细胞耗尽和
抗原耐受性。刺激的第二信号是由免疫系统的先天手臂产生的,当
例如,通过Toll样受体的信号诱导B7家族配体B7-1(CD80)和B7-2的表达
(CD86)表达于抗原提呈细胞。B7-1/B7-2的表达表明正在发生抗原提呈
在持续的先天免疫反应的背景下。B7-1和B7-2被TCR CD28识别
能有效增强TCR产生的T细胞激活信号的辅助受体。抑制性第二信号出现
在慢性刺激TCR信号的过程中。它们对于限制附带损害很重要。
由免疫反应和避免自身免疫引起,但它们也可能是有害的。为
例如,肿瘤细胞通常表达B7-家族配体B7-H1(PD-L1/CD274)和B7-DC(PD-DCs)。
L2/CD273),可被PD-1识别,PD-1是一种TCR辅助受体,可抑制TCR产生的T细胞激活
信号。B7-H1/B7-DC的表达向肿瘤细胞传递免疫豁免。出于这些和其他原因,它是
当务之急是提高我们对检查站信号的基本理解。在这里,我们建议将
PD-1调节Jurkat E6-1、HUT 78和TALL-104细胞酪氨酸磷酸化的动力学
CRISPR工程细胞来源于这些亲本细胞系和原代人类CD8+细胞。我们会申请
定量质谱学(MS)以获得无偏的、几乎全面的磷酸酪氨酸图像
T细胞群体中有无PD-1/CD28共受体信号的(PTyr)位点丰度随时间的变化
并且跨越各种条件。同时,使用荧光显微镜和工程SH2结构域亲和
试剂,我们将表征TCR,CD28和PD-1的多位点磷酸化的单分子模式。
我们还将测量这些细胞胞质信号伙伴的膜募集寿命
感受器。所产生的数据将用于驱动详细的
TCR信号机制模型解释了CD28和PD-1共激活的影响。虽然PD-1
被视为一个招募磷酸酶的平台,它抵消了来自激酶的激活信号,我们将
评估关于PD-1如何潜在地产生T细胞激活的积极信号的具体假设。
这些假说的动机是这样一个事实,即PD-1最典型的信号伙伴是蛋白质
酪氨酸磷酸酶,SHP1和SHP2,已知在其他环境中通过促进细胞激活,
例如,介导抑制pTyr位点的去磷酸化。模型预测将得到检验。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
William S Hlavacek其他文献
William S Hlavacek的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('William S Hlavacek', 18)}}的其他基金
System Dynamics of PD-1 Signaling in T Cells
T 细胞中 PD-1 信号传导的系统动力学
- 批准号:
10399590 - 财政年份:2021
- 资助金额:
$ 78.46万 - 项目类别:
Multiscale Modeling to Optimize Inhibition of Oncogenic ERK Pathway Signaling
多尺度建模优化致癌 ERK 通路信号传导的抑制
- 批准号:
10558581 - 财政年份:2020
- 资助金额:
$ 78.46万 - 项目类别:
Multiscale Modeling to Optimize Inhibition of Oncogenic ERK Pathway Signaling
多尺度建模优化致癌 ERK 通路信号传导的抑制
- 批准号:
10337242 - 财政年份:2020
- 资助金额:
$ 78.46万 - 项目类别:
Computational Model of Autophagy-Mediated Survival in Chemoresistant Lung Cancer
自噬介导的化疗耐药肺癌生存的计算模型
- 批准号:
9547104 - 财政年份:2017
- 资助金额:
$ 78.46万 - 项目类别:
Computational Model of Autophagy-Mediated Survival in Chemoresistant Lung Cancer
自噬介导的化疗耐药肺癌生存的计算模型
- 批准号:
9769647 - 财政年份:2017
- 资助金额:
$ 78.46万 - 项目类别:
Computational Model of Autophagy-Mediated Survival in Chemoresistant Lung Cancer
自噬介导的化疗耐药肺癌生存的计算模型
- 批准号:
9139424 - 财政年份:2015
- 资助金额:
$ 78.46万 - 项目类别:
Hardening Software for Rule-based models-Competitive Revision
基于规则的模型的强化软件 - 竞争性修订
- 批准号:
10382135 - 财政年份:2014
- 资助金额:
$ 78.46万 - 项目类别:
相似海外基金
Multidimensional development of high-affinity anti-glycan antibodies to fight deadly bacterial infections
多维开发高亲和力抗聚糖抗体以对抗致命细菌感染
- 批准号:
10549640 - 财政年份:2023
- 资助金额:
$ 78.46万 - 项目类别:
Computational modelling and simulation of antibodies to enhance binding affinity of a potential Burkholderia pseudomallei therapeutic
抗体的计算模型和模拟,以增强潜在的鼻疽伯克霍尔德氏菌治疗剂的结合亲和力
- 批准号:
2750554 - 财政年份:2021
- 资助金额:
$ 78.46万 - 项目类别:
Studentship
Affinity Biosensors for COVID-19 Antibodies
适用于 COVID-19 抗体的亲和生物传感器
- 批准号:
61319 - 财政年份:2020
- 资助金额:
$ 78.46万 - 项目类别:
Feasibility Studies
Directed Evolution of HIV Broadly Neutralizing Antibodies Using a Novel CRISPR-Engineered B cell in Vitro Affinity Maturation Platform
使用新型 CRISPR 工程 B 细胞在体外亲和力成熟平台定向进化 HIV 广泛中和抗体
- 批准号:
10013588 - 财政年份:2020
- 资助金额:
$ 78.46万 - 项目类别:
Affinity maturation and property changes of single-domain antibodies through repeated immunizations.
通过重复免疫,单域抗体的亲和力成熟和性质变化。
- 批准号:
20K07009 - 财政年份:2020
- 资助金额:
$ 78.46万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Rapid structure-based software to enhance antibody affinity and developability for high-throughput screening: Aiming toward total in silico design of antibodies
基于快速结构的软件可增强抗体亲和力和高通量筛选的可开发性:旨在实现抗体的全面计算机设计
- 批准号:
10603473 - 财政年份:2020
- 资助金额:
$ 78.46万 - 项目类别:
IN SILICO DESIGN OF HIGH-AFFINITY RECOMBINANT ANTIBODIES
高亲和力重组抗体的计算机模拟设计
- 批准号:
2342674 - 财政年份:2020
- 资助金额:
$ 78.46万 - 项目类别:
Studentship
Strategies for generating high affinity antibodies against Gram negative bacteria
产生针对革兰氏阴性菌的高亲和力抗体的策略
- 批准号:
10117194 - 财政年份:2020
- 资助金额:
$ 78.46万 - 项目类别:
Directed Evolution of HIV Broadly Neutralizing Antibodies Using a Novel CRISPR-Engineered B cell in Vitro Affinity Maturation Platform
使用新型 CRISPR 工程 B 细胞在体外亲和力成熟平台定向进化 HIV 广泛中和抗体
- 批准号:
10115604 - 财政年份:2020
- 资助金额:
$ 78.46万 - 项目类别:
Interdisciplinary protein engineering approach to design high affinity antibodies for flaviviruses
跨学科蛋白质工程方法设计黄病毒高亲和力抗体
- 批准号:
10294224 - 财政年份:2018
- 资助金额:
$ 78.46万 - 项目类别:














{{item.name}}会员




